


638 T7 promoter/priming site ↓
 TAATACGACT CACTATAGGG AGACCCAAGC TGGCTAGCGT TTAAACTTAA GCTTGGTACC GAGCTCGGAT
 ATTATGCTGA GTGATATCCC TCTGGGTTCG ACCGATCGCA AATTTGAATT CGAACCATGG CTCGAGCCTA

708 BstX I EcoR I PCR Product EcoR I Pst I EcoR V
 CCACTAGTCC AGTGTGGTGG AATTCGGCTT AAGCCG AATTCTGCAG ATATCCAGCA
 GGTGATCAGG TCACACCACC TTAAGCCGAA TTCGGC TTAAGACGTC TATAGGTCGT

763 BstX I Not I Xho I Xba I Apa I Pme I BGH reverse priming
 CAGTGGCGGC CGCTCGAGTC TAGAGGGCCC GTTTAAACCC GCTGATCAGC CTCGACTGTG CCTTCTA
 GTCACCGCCG GCGAGCTCAG ATCTCCCGGG CAAATTTGGG CGACTAGTCG GAGCTGACAC GGAAGAT



Comments for pCR® 3.1
5060 nucleotides

- CMV promoter: bases 1-596
- Putative transcriptional start: bases 620-625
- T7 promoter/priming site: bases 638-657
- Multiple cloning site: bases 670-801
- TA Cloning® site: 737-738
- BGH reverse priming site: bases 813-831
- BGH polyadenylation site: bases 812-1026
- pUC origin: bases 1116-1789
- SV40 promoter and origin: bases 3194-3532 (complement)
- Neomycin/kanamycin resistance gene (ORF): bases 2371-3159 (complement)
- Thymidine kinase polyadenylation site: bases 1926-2196 (complement)
- Ampicillin resistance gene (ORF): bases 3611-4471 (complement)
- f1 origin: bases 4602-5058